Effect of anandamide on nonadrenergic noncholinergic-mediated relaxation of rat corpus cavernosum

European Journal of Pharmacology

Volumn 544, Issue 1-3, 2006, Pages 138-145

  Ghasemi, Mehdi ^a   Sadeghipour, Hamed ^a   Mani, Ali R ^b   Tavakoli, Sina ^a   Hajrasouliha, Amir Reza ^a   Ebrahimi, Farzad ^a   Dehpour, Ahmad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

(Rat); Anandamide; Cannabinoid; Corpus cavernosum; NANC (nonadrenergic noncholinergic) relaxation; NO (nitric oxide)

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; ATROPINE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CAPSAZEPINE; GUANETHIDINE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; VANILLOID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATTENUATION; CHOLINERGIC SYSTEM; CONCENTRATION RESPONSE; CORPUS CAVERNOSUM; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; ELECTROSTIMULATION; MALE; MUSCLE CONTRACTILITY; MUSCLE RELAXATION; NONHUMAN; NORADRENERGIC SYSTEM; OXYGENATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

ANIMALS; ARACHIDONIC ACIDS; BLOTTING, WESTERN; CANNABINOIDS; CYCLOOXYGENASE INHIBITORS; ENDOCANNABINOIDS; INDOMETHACIN; MALE; MUSCLE RELAXATION; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE; PENIS; POLYUNSATURATED ALKAMIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHOLINERGIC;

EID: 33746598540     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.06.002     Document Type: Article

References (66)

1. Abel E.L. Marihuana: the First Twelve Thousands Years (1980), Plenum Press, New York
2. Andersson K.E. Clinical pharmacology of potassium channel openers. Pharmacol. Toxicol. 70 (1992) 244-254
3. Andersson K.E. Pharmacology of penile erection. Pharmacol. Rev. 53 (2001) 417-450
4. Andersson K.E. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J. Urol. 170 (2003) s6-s14
5. Burnett A.L. Role of nitric oxide in the physiology of erection. Biol. Reprod. 52 (1995) 485-489
6. Burstein S. Eicosanoids as mediators of cannabinoid action. In: Murphy L., and Bartke A. (Eds). Marijuana/Cannabinoids (1992), CRC Press, Boca Raton, FL 73-91
7. Burstein S.H., Young J.K., and Wright G.E. Relationships between eicosanoids and cannabinoids. Are eicosanoids cannabimimetic agents?. Biochem. Pharmacol. 50 (1995) 1735-1742
8. Chaytor A.T., Martin P.E.M., Evans W.H., Randall M.D., and Griffith T.M. The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J. Physiol. 520 (1999) 539-550
9. Christ G.J. Gap junctions and ion channels: relevance to erectile dysfunction. Int. J. Impot. Res. 12 (2000) S15-S25
10. Christ G.J., Rehman J., Day N., Salkoff L., Valcic M., Melman A., and Geliebter J. Intracorporal injection of hSlo cDNA in rats produces physiologically relevant alterations in penile function. Am. J. Physiol. 275 (1998) H600-H608
11. Da Silva G.E., Fernandez M.S., and Takahashi R.N. Potentiation of penile erection and yawning responses to apomorphine by cannabinoid receptor antagonist in rats. Neurosci. Lett. 25 (2003) 349-352
12. Deutsch D.G., and Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46 (1993) 791-796
13. Deutsch D.G., Goligorsky M.S., Schmid P.C., Krebsbach R.J., Schmid H.H.O., Das S.K., Dey S.K., Arreaza G., Thorup C., Stefano G., and Moore L.C. Production and physiological actions of anandamide in the vasculature of the rat kidney. J. Clin. Invest. 100 (1997) 1538-1546
14. Devane W.A., Dysarz F.A.I., Johnson M.R., Melvin L.S., and Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34 (1988) 605-613
15. Devane W.A., Hanuš L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., and Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
16. G-nitro-l-arginine, a NO synthase inhibitor, on NE overflow and antidiuresis induced by stimulation of renal nerves in anesthetized dogs. J. Pharmacol. Exp. Ther. 269 (1994) 529-535
17. Felder C.C., and Glass M. Cannabinoid receptors and their endogenous agonists. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 179-200
18. Ferrari F., Ottani A., and Giuani D. Inhibitory effects of the cannabinoid agonist on rat sexual behaviour. Physiol. Behav. 69 (2000) 547-554
19. Fimiani C., Mattocks D., Cavani F., Salzet M., Deutsch D.G., Pryor S., Bilfinger T.V., and Stefano G.B. Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. Cell. Signal. 11 (1999) 189-193
20. Fleming I., Schermer B., Popp R., and Busse R. Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. Br. J. Pharmacol. 126 (1999) 949-960
21. Fulton D., and Quilley J. Evidence against anandamide as the hyperpolarizing factor mediating the nitric oxide-independent coronary vasodilator effect of bradykinin in the rat. J. Pharmacol. Exp. Ther. 286 (1998) 1146-1151
22. Giraldi A., and Wagner G. Effects of pinacidil upon penile erectile tissue, in vitro and in vivo. Pharmacol. Toxicol. 67 (1990) 235-238
23. Grainger J., and Boachie-Ansah G. Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br. J. Pharmacol. 134 (2001) 1003-1012
24. Harris D., McCulloch A.I., Kendall D.A., and Randall M.D. Characterization of vasorelaxation responses to anandamide in the rat mesenteric arterial bed. J. Physiol. 15 539 (2002) 893-902
25. Hedlund P., Holmquist F., Hedlund H., and Andersson K.E. Effects of nicorandil on human isolated corpus cavernosum and cavernous artery. J. Urol. 151 (1994) 1107-1113
26. Heinemann A., Shahabazian A., and Holzer P. Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropsychopharmacology 38 (1999) 1289-1297
27. Herer J. The Emperor Wears No Clothes: the Authoritative Historical Record Of Cannabis and the Conspiracy Against Marijuana. 11th ed. (1998), AH HA publishing Co, New York
28. Howlett A.C., and Mukhopadhyay S. Cellular signal transduction by anandamide and 2-arachidonoylglycerol. Chem. Phys. Lipids 108 (2000) 53-70
29. Howlett A.C., Bidaut-Russell M., Devane W.A., Melvin L.S., Johnson M.R., and Herkenham M. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 13 (1990) 420-423
30. Ignarro L.J., Bush P.A., Buga G.M., Wood K.S., Fukuto J.M., and Rajfer J. Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem. Biophys. Res. Commun. 170 (1990) 830-843
31. 2 receptors. PNAS 96 (1999) 14136-14141
32. Kim N., Azadzoi K.M., Goldstein I., and de Tejada I. A nitric oxide-like factor mediates nonadrenergic noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J. Clin. Invest. 88 (1991) 112-118
33. Kunos G., Járai Z., Bátkai S., Goparaju S.K., Ishac E.J.N., Liu J., Wang L., and Wagner J.A. Endocannabinoids as cardiovascular modulators. Chem. Phys. Lipids 108 (2000) 159-168
34. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.-F., Beslot F., Böhme G.A., Imperato A., Pedrazzini T., Roques B.P., et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283 (1999) 401-404
35. Lee S.W., Wang H.Z., and Christ G.J. Characterization of ATP-sensitive potassium channels in human corporal smooth muscle cells. Int. J. Impot. Res. 11 (1999) 179-188
36. Lue T.F. Erectile dysfunction. N. Eng. J. Med. 342 (2000) 1802-1813
37. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., and Bonner T.I. Structure of cannabinoid receptor and functional expression of the cloned cDNA. Nature 346 (1990) 561-564
38. Mechoulam R., Fride E., and Di Marzo V. Endocannabinoids. Eur. J. Pharmacol. 359 (1998) 1-18
39. Melis M.R., Succu S., Mascia M.S., and Argiolas A. Antagonism of cannabinoid CB1 receptors in the paraventricular nucleus of male rats induces penile erection. Neurosci. Lett. 359 (2004) 17-20
40. 2+ in endothelial cells. Br. J. Pharmacol. 126 (1999) 1593-1600
41. Moon D.G., Byun H.S., and Kim J.J. A KATP-channel opener as a potential treatment modality for erectile dysfunction. BJU Int. 83 (1999) 837-841
42. Mukhopadhyay S., Chapnick B.M., and Howlett A.C. Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent. Am. J. Physiol, Heart Circ. Physiol. 282 (2002) H2046-H2054
43. Munro S., Thomas K.L., and Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365 (1993) 61-65
44. Nieri P., Martinotti E., Testai L., Martinelli C., and Breschi M.C. Effects of cannabinoids on non-adrenergic non-cholinergic-mediated relaxation in guinea-pig trachea. Eur. J. Pharmacol. 475 (2003) 115-118
45. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6 (1999) 635-664
46. Ralevic V., Kendall D.A., Randall M.D., Zygmunt P.M., Movahed P., and Högestätt E.D. Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed. Br. J. Pharmacol. 130 (2000) 1483-1488
47. Randall M.D., and Kendall D.A. Involvement of an endogenous cannabinoid in EDHF-mediated vasorelaxation in the rat coronary vasculature. Eur. J. Pharmacol. 335 (1997) 205-209
48. Randall M.D., and Kendall D.A. Endocannabinoids: a new class of vasoactive substances. Trends Pharmacol. Sci. 19 (1998) 55-58
49. Randall M.D., Alexander S.P.H., Bennett T., Boyd E.A., Fry J.R., Gardiner S.M., Kemp P.A., Mc Culloch A.I., and Kendall D.A. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem. Biophys. Res. Commun. 229 (1996) 114-120
50. 1 receptors, nitric oxide and potassium channels. Br. J. Pharmacol. 147 (2006) 917-925
51. Ross R.A., Gibson T.M., Brockie H.C., Leslie M., Pashmi G., Craib S.J., Di Marzo V., and Pertwee R.G. Structure-activity relationship for the endogenous cannabinoid, anandamide and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br. J. Pharmacol. 132 (2001) 631-640
52. Sadeghipour H., Dehghani M., and Dehpour A.R. Role of opioid and nitric oxide system in the nonadrenergic noncholinergic-mediated relaxation of corpus cavernosum in bile duct-ligated rats. Eur. J. Pharmacol. 460 (2003) 201-207
53. 9-THC is not dependent on changes in plasma testosterone or hypothalamic dopamine or serotonin content. Pharmacol. Biochem. Behav. 22 (1985) 415-420
54. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., and Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129 (2000) 227-230
55. Smart D., Jerman J.C., Gunthorpe M.J., Brough S.J., Ranson J., Cairns W., Hayes P.D., Randall A.D., and Davis J.B. Characterisation using FLIPR of human vanilloid VR1 receptor pharmacology. Eur. J. Pharmacol. 417 (2001) 51-58
56. Stefano G.B., Salzet M., Magazine H.I., and Bilfinger T.V. Antagonism of LPS and INF-γ induction of iNOS in human saphenous vein endothelium by morphine and anandamide by NO inhibition of adenylate cyclase. J. Cardiovas. Pharmacol. Ther. 31 (1998) 813-820
57. Storr M., Gaffal E., Saur D., Schusdziarra V., and Allescher H.D. Effect of cannabinoids on neural transmission in rat gastric fundus. Can. J. Physiol. Pharm. 80 (2002) 67-76
58. Tognetto M., Amadesi S., Harrison S., Creminon C., Trevisani M., Carreras M., Matera M., Geppetti P., and Bianchi A. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J. Neurosci. 21 (2001) 1104-1109
59. Venkateswarlu K., Giraldi A., Zhao W., Wang H.Z., Melman A., Spektor M., and Christ G.J. Potassium channels and human corporal smooth muscle cell tone: diabetes and relaxation of human corpus cavernosum smooth muscle by adenosine triphosphate sensitive potassium channel openers. J. Urol. 168 (2002) 355-361
60. Wagner J.A., Varga K., Járai Z., and Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33 (1999) 429-434
61. Wagner J.A., Járai Z., Bátkai S., and Kunos G. Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB receptors. Eur. J. Pharmacol. 423 (2001) 203-210
62. Wang H.Z., Lee S.W., and Christ G.J. Comparative studies of the maxi-K (K(Ca)) channel in freshly isolated myocytes of human and rat corpora. Int. J. Impot. Res. 12 (2000) 9-18
63. White R., and Hilley C.R. A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br. J. Pharmacol. 122 (1997) 1573-1584
64. White R., Ho W.S., Bottrill F.E., Ford W.R., and Hilfsey C.R. Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br. J. Pharmacol. 134 (2001) 921-929
65. Zygmunt P.M., Högestätt E.D., Waldeck K., Edwards G., Kirkup A.J., and Weston A.H. Studies on the effects of anandamide in rat hepatic artery. Br. J. Pharmacol. 122 (1997) 1679-1686
66. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgård M., Di Marzo V., Julius D., and Högestätt E.D. Vanilloid receptors on sensory nerve mediate the vasodilator action of anandamide. Nature 400 (1999) 452-457